Cash, cash equivalents and short-term bank deposits slipped to $6.7 million at June 30 from $8 million at March 31.
Liquidity is expected to fund operations through Q1 2027; the proposed all-stock merger with Scipher is expected to close before the end of 2026.
The combined company is valued at $150 million pre-$30 million private placement; the nebokitug Phase 2 RA trial is slated to start in H1 2027, with readout in H1 2028.
Q2 loss widens slightly as spending shifts
Chemomab posted a Q2 net loss of $2.2 million, versus a $2.1 million loss a year earlier.
R&D spending fell to $1.1 million from $1.3 million, while G&A costs edged up to $1.1 million from $1 million.
CMMB•
